Lower China Growth For Takeda, But Impact Limited
This article was originally published in PharmAsia News
Executive Summary
In line with some of its larger multinational peers, Takeda saw weaker growth in China over the past three months, although its relatively small exposure to emerging markets and increases for new products in major markets mean investors do not appear concerned.